PGI Is Contemplating To Start In-House Testing Of Medicines

CHANDIGARH : After the recent cases of drug contamination and adverse events at PGI, the institute is contemplating to start in-house testing of medicines, a facility lacking in any public hospital in the country.

There are regional and central drugs laboratories and some private centres which are approved by the DCGI to test and analyse suspected medicine samples. No hospital has the large scale facility or infrastructure for testing medicine safety and efficacy.

“We are actively working on it. It should be operational sooner than later. It will be a double check. We will not have to depend on outside resources,” said Prof Vivek Lal, director, PGI.

After five deaths of patients who were to be operated upon and were administered sedative drug Propofol, the PGI had sent the samples of the medicine to the drug control authorities in the city. It took almost a month for the test analysis report. With the in-house testing, the hospital will be able to conclude with evidence if the adverse event was due to the medicines or other complications.

“The sample was also tested by the pharmacology department in the PGI and in Panjab University. But in the absence of the requisite infrastructure/reagents, the test was not as validated as from the approved government testing laboratories,” said a faculty member at PGI.

The laboratory will follow pharmacopoeia monographs — documents which are taken as reference for testing of drugs — and had to be good manufacturing practice compliant. “When the facility is ready, suspected drugs will be tested here prior to giving it to the patients who are admitted for surgery or for treatment. However, for any legal action, the samples will also be sent to the approved government laboratories,” said a senior faculty member.

  • Related Posts

    Licences of 20 medical stores suspended after inspections

    Drug Control Department inspects 120 medical stores; 32 NDPS cases and 63 arrests recorded in 2026 so far The district administration has intensified action against illegal drug sale and distribution,…

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    NEW DELHI: Global investment firm Bain Capital has divested nearly a 1 per cent stake in Emcure Pharmaceuticals for over Rs 289 crore through open market transactions, according to the…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert

    Civil society group SAM calls for greater transparency involving clinical trials

    Civil society group SAM calls for greater transparency involving clinical trials

    Different packaging, typos expose fake Mounjaro racket

    Different packaging, typos expose fake Mounjaro racket